This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DMK Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Eddie Glover

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

CEO

Eddie Glover (74 yo)

no data

Görev süresi

Mr. Eddie Wabern Glover serves as Chief Executive Officer of US Compounding Inc at DMK Pharmaceuticals Corporation (formerly known as Adamis Pharmaceuticals Corporation). He co-founded US Compounding, Inc....

This company listing is no longer active

DMK Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024

DMK Pharmaceuticals Corporation Announces CFO Changes

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023

Adamis Pharmaceuticals Corporation Announces Chief Financial Officer Changes

Adamis Pharmaceuticals Corporation Appoints Vickie Reed to Board of Directors

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Recent updates

Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals Corporation

First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation

Nasdaq to Delist Common Stock of DMK Pharmaceuticals

DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index

DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024

DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI

Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock Market

DMK Pharmaceuticals Corporation Announces CFO Changes

DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirements

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023

Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.

Adamis Pharmaceuticals Corporation Announces Chief Financial Officer Changes

Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023

Adamis Pharmaceuticals Corporation to Report Q3, 2022 Results on Nov 14, 2022

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceutics Corporation Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation to Report Q2, 2022 Results on Aug 10, 2022

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of Covid-19

Adamis Pharmaceuticals Corporation announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation Appoints Vickie Reed to Board of Directors

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Adamis Pharmaceuticals Corporation to Report Q1, 2022 Results on May 16, 2022

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Richard C. Williams Notifies Adamis Pharmaceuticals Corporation That Effective April 15, 2022, He Will Be Retiring

Less than half of directors are independent

Adamis Pharmaceuticals Corporation’S Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

Adamis Pharmaceuticals Corporation Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Adamis Pharmaceuticals Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 Mg Intramuscular Dose of Naloxone in Zimhi™

Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

Adamis Pharmaceuticals Receives A Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

An unknown buyer completed the acquisition of U.S. Compounding, Inc. from Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) for $15 million.

Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19

Adamis Provides Update on ZIMHI™

Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19

Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ

Adamis Pharmaceuticals Corporation announced delayed amended 10-Q filing

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

Adamis Pharmaceuticals Corporation announced delayed annual 10-K filing

Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the Covid-19 Challenged Hamster Model

Adamis Pharmaceuticals Corporation Clears to Proceed with Human Studies of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Strengthens Patent Portfolio for its Naloxone Product Candidate

Adamis Pharmaceuticals Corporation has completed a Follow-on Equity Offering in the amount of $44.999999 million.

Adamis Pharmaceuticals Corporation Announces the Availability of SYMJEPI Products in the Walgreens Prescription Savings Club

CEO

Görev süresi